Bob Herman

Bob Herman follows the flow of money through health care, tracking how insurers, hospitals, and policymakers turn regulation and benefits design into revenue and risk for patients and taxpayers. He is a business of health care reporter at STAT, where he concentrates on health insurance, hospital finances, and the corporate structures behind medical care. His work leans on government rules, lawsuits, and financial data to show how industry strategy drives Medicare Advantage payouts, employer coverage trends, and the affordability of care.

Medicare Advantage ratings, bonuses, and volatility

Herman’s reporting on Medicare Advantage centers on how federal quality ratings translate into billions of dollars in bonus payments for insurers. In one recent story, he explains how the Centers for Medicare and Medicaid Services recalculated quality ratings for 2026 plans after a new legal challenge from the health insurance industry, emphasizing that changes in star scores can jeopardize or restore large taxpayer-funded bonuses. He notes that insurers have flooded the government with lawsuits over low ratings in recent years, with mixed success that has forced CMS to redo scores and inject added volatility into the program.

His coverage quantifies the stakes, pointing out that plans earning at least four stars receive bonus payments that have grown to around $16 billion in a single year, roughly the size of the Centers for Disease Control and Prevention’s budget and double the amount from 2020. In earlier work, he traces how regulatory changes to the measures used in star ratings produce an estimated $18.6 billion windfall for Medicare Advantage insurers over a decade, underscoring how technical rule tweaks reshape the economics of the program.

Across these pieces, he focuses on who gains and who pays when the government adjusts ratings, making a complex policy regime legible through its financial consequences.

Corporate power, insurers, and legal fights

Herman frequently scrutinizes the behavior of major health care corporations, especially UnitedHealth and large hospital systems. He has covered an Internal Revenue Service probe into UnitedHealth Group’s taxes and the slowdown of private equity-style deals for physician groups, tying corporate expansion strategies to regulatory and tax scrutiny. In another story, he reports on UnitedHealth executives directing substantial campaign donations to a high-ranking Democrat ahead of elections, framing the contributions in the context of ongoing debates over health policy and Medicare reform.

His work also follows legal disputes between hospitals and insurers, including a case in which HCA’s hospitals sued an out-of-state Blue Cross Blue Shield plan over denied claims and prior authorization decisions.

On the pharmaceutical side, he has detailed Cigna’s acquisition of CarepathRx, a major pharmacy operation, as part of broader vertical integration that brings specialty pharmacy services under insurer control. These pieces consistently link corporate deals, legal fights, and political spending back to their impact on market concentration, payment practices, and the leverage health care giants hold over patients and employers.

Employer insurance and the cost burden on patients

Beyond government programs, Herman devotes significant attention to the erosion of employer health insurance and the financial strain it places on people who rely on job-based coverage. In coverage of an affordability series titled “Out of Pocket, Out of Reach,” he distills why health insurance costs so much, highlighting how premiums, deductibles, and other out-of-pocket charges combine to make coverage difficult to use even when people technically have insurance. He returns to the theme in his reporting on the “decaying” state of America’s employer health insurance, describing how rising medical claims and benefit costs are reshaping what companies offer and what workers can afford. His stories on UnitedHealth’s signals about employer health insurance costs connect earnings expectations and medical spending trends to the future of job-based coverage, making clear that corporate guidance translates into real changes in benefits and household budgets. Across this strand of his beat, Herman’s distinction is his focus on the financial mechanics - claims trends, benefit design, and insurer margins - rather than treating employer insurance as a static benefit.

Health Care Inc. newsletter and investigative projects

Herman extends his reporting through Health Care Inc., STAT’s weekly newsletter on the business of health and medicine. The newsletter gathers his coverage of insurers, hospitals, and pharmacies into a regular briefing, often unpacking one central theme such as political spending by health care companies, surprise billing debates, or shifting tax enforcement.

He uses the newsletter format to blend reported stories, quick analysis of corporate filings, and reader questions, maintaining a consistent focus on how business decisions shape care and costs.

The Health Care Inc. brand has become a central channel for his work, with multiple STAT articles identifying him as its author and framing stories as extensions of the newsletter’s lens on the health care industry. Herman’s background includes prior reporting roles at national health care and policy outlets, and he has received major recognition as a Pulitzer co-finalist for the series “Denied by AI” and a co-recipient of a George Polk Award for “Health Care’s Colossus,” both investigations into the intersection of technology, corporate power, and patient care.

That investigative experience reinforces his current beat, where he treats health care finance not as abstract numbers but as evidence of how institutions distribute risk, profit, and care.